



PRESS RELEASE

06 November 2024 13:00:00 CET

Continued efforts expand AcouSort's presence in the flow cytometry space

In order to further strengthen its presence in the flow cytometry space, AcouSort has initiated two important collaborations placing instruments at University of Ottawa, Canada, and Van Andel Institute, Michigan, USA, respectively.

As earlier reported, AcouSort collaborates with Dr Vera Tang at University of Ottawa to develop applications concerning isolation of cells from dissociate tissue samples. The collaboration has been very successful and resulted in a poster presented by Dr. Tang at the CYTO conference in May 2024. The application has gained substantial interest as it has potential to significantly improve the workflow and analysis of dissociated tissue samples.

To build on the knowledge generated by Dr Tang and extend the AcouWash sample preparation procedure to other tissue types, AcouSort has initiated a collaboration with Dr Rachel Sheridan at Van Andel Institute, Michigan, USA. Dr Sheridan and her team will work with the AcouWash system to develop and optimize cell isolation from dissociated tissue in parallel with Dr Tang.

To further facilitate the work of Dr Tang, AcouSort has now placed an AcouTrap system at the University of Ottawa to be used for the development of EV and Virus isolation for flow cytometry analysis.

“We await the results from these collaborations with great excitement. Being able to build data together with leading scientists in different fields is an important part of our strategy to expand and independently document the use of our unique technology,” says Agnes Michanek, Commercial Director at AcouSort.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of-Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).



PRESS RELEASE

06 November 2024 13:00:00 CET